Alzamend Neuro Inc (ALZN) - Total Liabilities
Based on the latest financial reports, Alzamend Neuro Inc (ALZN) has total liabilities worth $1.86 Million USD as of January 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ALZN net assets growth trend to track the company's year-over-year net asset growth rate.
Alzamend Neuro Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Alzamend Neuro Inc's total liabilities have evolved over time, based on quarterly financial data.
Alzamend Neuro Inc Competitors by Total Liabilities
The table below lists competitors of Alzamend Neuro Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tenon Medical Inc
NASDAQ:TNON
|
USA | $10.94 Million |
|
H&T Group plc
LSE:HAT
|
UK | GBX98.53 Million |
|
Sherpa II Holdings Corp
V:SHRP
|
Canada | CA$290.13K |
|
McBride plc
LSE:MCB
|
UK | GBX411.00 Million |
|
Shamaym Improve Ltd
TA:SHMM
|
Israel | ILA803.40K |
|
NORTHSTAR GOLD CORP.
F:3WV
|
Germany | €1.14 Million |
|
Century Global Commodities Corp
TO:CNT
|
Canada | CA$2.92 Million |
|
Americore Resources Corp.
V:AMCO
|
Canada | CA$123.70K |
Liability Composition Analysis (2016–2025)
This chart breaks down Alzamend Neuro Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALZN stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alzamend Neuro Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alzamend Neuro Inc (2016–2025)
The table below shows the annual total liabilities of Alzamend Neuro Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | $634.76K | -80.32% |
| 2024-04-30 | $3.23 Million | +12.39% |
| 2023-04-30 | $2.87 Million | +146.38% |
| 2022-04-30 | $1.16 Million | +29.49% |
| 2021-04-30 | $899.64K | -9.34% |
| 2020-04-30 | $992.31K | -16.19% |
| 2019-04-30 | $1.18 Million | +1124.10% |
| 2018-04-30 | $96.72K | -86.51% |
| 2017-04-30 | $717.22K | +2234.71% |
| 2016-04-30 | $30.72K | -- |
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neur… Read more